Response from Sofinnova Partners to Risky Business report
As a long-term investor across the bio-pharmaceutical, biotechnology and medical sectors, Sofinnova Partners has always recognised the positive environmental and social impact of its investments, which ultimately extend and improve the quality of life for an incalculable number of people across the globe. In 2011, Sofinnova formally documented and institutionalised its first ESG policy. An ESG charter has been published on our website since 2018 and in its current incarnation is called our Responsible Investor Policy (https://www.sofinnovapartners.com/terms-and-conditions). This document specifically refers to our desire to respect and support internationally recognized fundamental human and labour rights as well as the promotion of diversity, equity, and inclusion.
... Sofinnova is committed to the principles of sustainable development and corporate social responsibility... Responsible investing is a process that is present at every point of our investment lifecycle and is kept on the agenda at all times both in our portfolio companies and within Sofinnova Partners... Equity, diversity and inclusion have always been core tenants of Sofinnova's values.